

DNA methylation signatures correlate with response to immune checkpoint inhibitors in metastatic melanoma

Julia Maria Ressler¹, Erwin Tomasich^{2,4}, Teresa Hatzioannou^{2,4}, Helmut Ringl³, Gerwin Heller⁴, Rita Silmbrod¹, Lynn Gottmann^{2,4}, Angelika Martina Starzer⁴, Nina Zila^{1,5}, Philipp Tschandl¹, Christoph Höller¹, Matthias Preusser^{2,4}, Anna Sophie Berghoff^{2,4}

- (1) Medical University of Vienna, Department of Dermatology, Vienna, Austria
- (2) Medical University of Vienna, Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Vienna, Austria
- (3) Wiener Gesundheitsverbund, Klinik Donaustadt, Vienna, Austria
- (4) Medical University of Vienna, Division of Oncology, Department of Medicine I, Vienna, Austria
- (5) University of Applied Sciences FH Campus Wien, Division of Biomedical Science, Vienna, Austria

Corresponding Author:

Anna Sophie Berghoff, MD

Division of Oncology & Christian Doppler Laboratory for Personalized Immunotherapy

Department of Medicine I

Medical University of Vienna

Waehringer Guertel 18-20

1090 Vienna, Austria

Phone number: +43 1 40 400 44450

E-mail: anna.berghoff@meduniwien.ac.at

SUPPLEMENTARY TABLE

Patient's clinical and tumor characteristics from patients with tumor tissue derived from different body sites

Sex (n; %)	
Female	4 (50.0%)
Male	4 (50.0%)
Age (years)	
Median	78 (range: 54-81 years)
Mutation status (n; %)	
BRAF	2 (25.0%)
NRAS	2 (25.0%)
cKIT	1 (12.5%)
wt	3 (39.0%)
Baseline ECOG (n; %)	
0	7 (87.5%)
1	1 (12.5%)
Baseline LDH (U/L)	
normal	6 (25.0%)
>ULN	2 (75.0%)
Baseline S100 (ug/L)	
normal	4 (50.0%)
> ULN	4 (50.0%)
Origin of treatment-naïve tumor tissue for methylation profiling (n; %)	
Primary tumor and organ metastatic lesion	1 (12.5%)
Primary tumor and lymph node metastatic lesion	2 (25.0%)
Cutaneous and lymph node metastatic lesion	3 (37.5%)
Primary tumor and cutaneous metastatic lesion	1 (12.5%)
Primary tumor, cutaneous and lymph node metastatic lesion	1 (12.5%)
First-line IO (n; %)	
Nivolumab monotherapy	4 (50.0%)
Pembrolizumab monotherapy	1 (12.5%)
Nivolumab and ipilimumab	3 (39.0%)
iBOR according to iRECIST (n; %)	
iCR	1 (12.5%)
iPD (iUPD or iCPD)	7 (87.5%)

Table S1. Patient's clinical and tumor characteristics from patients with tumor tissue derived from different body sites.

Wildtype (wt); lactate dehydrogenase (LDH); upper limit of normal (ULN); not applicable (NA); Eastern Cooperative Oncology Group (ECOG) performance status; Immunotherapy (IO); Response was classified according to immune-based Response Evaluation Criteria in Solid Tumors (iRECIST): best overall response (iBOR), immune complete response (iCR); immune partial response (iPR), immune stable disease

(iSD), immune progressive disease (iPD); immune unconfirmed progressive disease (iUPD); immune confirmed progressive disease (iCPD).




Figure S1. Methylation signature-based response to immune checkpoint inhibitors in metastatic melanoma of an independent validation cohort. A) Heatmap demonstrating three clusters based on the top 500 DMPs of the discovery cohort. Responders (R), non-responders (NR). Beta values ranging from 0 (blue) to 1 (red) are shown.